Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.67 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311905 | 1.00 | CHRNA7 (0.67) | CHRNA7EZH2MEN1NPC1RAB9A | |
| SCHEMBL6305169 | 0.94 | CHRNA7 (0.68) | CHRNA7EZH2MEN1NPC1RAB9A | |
| SCHEMBL6303571 | 0.90 | CHRNA7 (0.67) | CHRNA7EZH2DRD2DRD4CTSB | |
| SCHEMBL6303576 | 0.90 | CHRNA7 (0.67) | CHRNA7EZH2DRD2DRD4CTSB | |
| SCHEMBL6311218 | 0.90 | CHRNA7 (0.67) | CHRNA7EZH2DRD2DRD4CTSB | |
| SCHEMBL6311212 | 0.90 | CHRNA7 (0.67) | CHRNA7EZH2DRD2DRD4CTSB | |
| SCHEMBL6306329 | 0.89 | CHRNA7 (0.66) | CHRNA7EZH2MEN1KMT2ADRD2 | |
| SCHEMBL6305939 | 0.89 | CHRNA7 (0.86) | CHRNA7EZH2MEN1NPC1RAB9A | |
| SCHEMBL6305940 | 0.89 | CHRNA7 (0.86) | CHRNA7EZH2MEN1NPC1RAB9A | |
| SCHEMBL6303154 | 0.89 | CHRNA7 (0.66) | CHRNA7EZH2DRD2DRD4CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | claimed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1480977-A2 | SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003070728-A2 | AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | CHRNA7 2937/4885EZH2 4701/4885MEN1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.